title: Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics.
abstract: Double-filtration plasmapheresis (DFPP) was approved in Japan in April 2008 for the retreatment of chronic hepatitis C patients with genotype 1b and high viral loads, whose hepatitis C virus was not eradicated by earlier IFN therapy or by pegylated IFN plus ribavirin (PEG-IFN/RBV) combination therapy. In this study, we assessed the early viral dynamics of 9 patients with non-sustained virological response to the combination therapy. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks showed a reduction of > or =1 log in the viral load in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9) and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment. By contrast, DFPP plus consecutive intravenous IFN-beta for 4 weeks reduced the viral load by > or = 1 log in 33% (2/6), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks. The viral load declined by > or = 2 log in 50% (3/6) at 4 weeks after the start of treatment. DFPP plus consecutive intravenous IFN-beta for 4 weeks is a promising treatment for non-sustained virological response patients.
authors.affiliation: Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan. asahi-hp@arion.ocn.ne.jp
authors.forename: Soo Ryang
authors.initials: SR
authors.lastname: Kim
authors.forename: Susumu
authors.initials: S
authors.lastname: Imoto
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Keiji
authors.initials: K
authors.lastname: Mita
authors.forename: Miyuki
authors.initials: M
authors.lastname: Taniguchi
authors.forename: Ke Ih
authors.initials: KI
authors.lastname: Kim
authors.forename: Noriko
authors.initials: N
authors.lastname: Sasase
authors.forename: Ikuo
authors.initials: I
authors.lastname: Shoji
authors.forename: Motoko
authors.initials: M
authors.lastname: Nagano-Fujii
authors.forename: Ahmed
authors.initials: A
authors.lastname: El-Shamy
authors.forename: Hak
authors.initials: H
authors.lastname: Hotta
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nagai
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nagata
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005374:Filtration / Q000379:methods*; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000628:therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D016899:Interferon-beta / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D016899:Interferon-beta; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a